What is the recommended dual antiplatelet therapy (DAPT) regimen after percutaneous endovascular aneurysm repair (PEVAR) in an adult patient?

DAPT After PEVAR: Recommended Regimen

Based on current evidence, single antiplatelet therapy (SAPT) with aspirin 75-100 mg daily OR clopidogrel 75 mg daily is recommended after percutaneous endovascular aneurysm repair (PEVAR) for standard abdominal aortic aneurysm repair in patients without established atherosclerotic cardiovascular disease. 1

Evidence-Based Rationale

The most recent and highest-quality evidence directly addressing this question comes from a 2025 target trial emulation study of 8,325 patients undergoing standard EVAR 1. This study demonstrated that:

• DAPT provided no cardiovascular benefit over SAPT (HR 1.07,95% CI 0.93-1.22 for major adverse cardiac and cerebrovascular events)
• DAPT provided no procedural benefit (HR 1.07,95% CI 0.92-1.24 for AAA reintervention/surgery)
• DAPT significantly increased bleeding risk (HR 1.20,95% CI 1.02-1.41 for major or clinically relevant non-major bleeding)

Algorithm for Antiplatelet Selection After PEVAR

Standard EVAR (Infrarenal AAA):

• Start: Aspirin 75-100 mg daily OR clopidogrel 75 mg daily
• Duration: Lifelong (if no contraindications)
• Rationale: No evidence supports DAPT; increased bleeding without benefit 1

Complex Endovascular Repair (Fenestrated/Branched EVAR):

For patients WITHOUT independent indication for anticoagulation:

• Preferred regimen: DAPT (aspirin 75-100 mg + clopidogrel 75 mg daily)
• Duration: 3 months minimum, then transition to SAPT
• Rationale: DAPT showed improved branch vessel patency (sHR 0.72, p=0.045) without significantly increased bleeding compared to SAPT 2

For patients WITH independent indication for anticoagulation (e.g., atrial fibrillation):

• Avoid triple therapy: Use anticoagulation + single antiplatelet (clopidogrel preferred)
• Rationale: Anticoagulation plus antiplatelet tripled bleeding risk (HR 3.10, p=0.001) in branched EVAR 2

Critical Distinctions by Procedure Type

Standard EVAR vs. Complex EVAR:

The evidence clearly differentiates between standard infrarenal EVAR and complex fenestrated/branched procedures:

• Standard EVAR: Multiple recent studies 3, 4, 1 show no benefit of DAPT over SAPT
• Fenestrated/Branched EVAR: DAPT may reduce target vessel occlusion 3, 2, though one German study found no difference 4

The key factor is target vessel (branch/fenestration) involvement. Standard EVAR without branches does not benefit from DAPT, while complex repairs with multiple target vessels show potential benefit from short-term DAPT.

Peripheral Arterial Disease Guidelines Context

The 2024 ESC PAD guidelines 5 provide relevant context for lower extremity endovascular procedures:

• Standard recommendation: Single antiplatelet therapy (aspirin 75-160 mg OR clopidogrel 75 mg daily) for symptomatic PAD 5
• Enhanced therapy: Rivaroxaban 2.5 mg BID + aspirin 100 mg may be considered for high ischemic risk patients with non-high bleeding risk 5
• Post-revascularization: DAPT for at least 1 month after revascularization may be considered to reduce limb events 5
• Long-term DAPT not recommended in PAD patients 5

Common Pitfalls to Avoid

1. Do not extrapolate coronary PCI guidelines to EVAR: The 2022 ACC/AHA coronary revascularization guidelines 6 recommend DAPT after PCI, but this does NOT apply to standard aortic endografts

2. Medication non-adherence is critical: 26% of target vessel occlusions in one study occurred with documented cessation of antiplatelet therapy 3. Emphasize adherence regardless of regimen chosen

3. Aspirin vs. clopidogrel monotherapy matters: In subgroup analysis, clopidogrel monotherapy had significantly higher 1-year target vessel occlusion rates (17.1%) compared to aspirin (2.1%, p<0.001) 3

4. Do not continue DAPT long-term to "be safe": This increases bleeding without reducing thrombotic events in standard EVAR 1

Special Populations

Patients with concurrent coronary artery disease:

• If recent ACS (<12 months): Continue DAPT per cardiac indications 7, 6
• If stable CAD with remote PCI (>12 months): SAPT is sufficient 6, 8
• The cardiac indication takes precedence over the EVAR indication

Patients requiring anticoagulation (e.g., atrial fibrillation):

• Use oral anticoagulant (DOAC preferred) + clopidogrel 75 mg for 1 week to 1 month maximum 9, 10
• Then transition to anticoagulation alone 9, 10
• Avoid triple therapy beyond 1 week unless extremely high thrombotic risk 11

Strength of Evidence Assessment

The recommendation for SAPT in standard EVAR is supported by:

• Level A evidence from a large 2025 target trial emulation 1
• Consistent findings across multiple 2024-2026 studies 3, 2, 4
• A 2016 meta-analysis showing no benefit of DAPT across arterial territories 12

The recommendation for short-term DAPT in complex EVAR is supported by:

• Moderate-quality evidence from retrospective cohort studies 3, 2
• Conflicting data from one German center 4
• Biological plausibility given multiple small-caliber target vessels

The evidence strongly favors SAPT for standard EVAR and suggests considering 3-month DAPT for complex fenestrated/branched repairs, with immediate transition to SAPT in patients requiring anticoagulation.